Results 1 to 10 of about 119,881 (373)
Frontiers in Immunology, 2021 Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse complications of allogeneic transplantation which still cause substantial morbidity and mortality despite significant advances in supportive care over the last few decades. The prevention of GVHD therefore remains critical to the success of allogeneic transplantation.
Mahasweta Gooptu, Joseph Harry Antin
openaire +4 more sources
miR-204–containing exosomes ameliorate GVHD-associated dry eye disease
Science Advances, 2022 MSC-exo eye drops alleviate GVHD-associated dry eye disease by shifting M1 macrophages to M2 via miR-204.
Tian Zhou, Chang He, Ziqi Yang
exaly +3 more sources
Hematology, 2018 Abstract Acute graft-versus-host disease (GVHD) targets the crypts in the gastrointestinal (GI) tract that are responsible for the self-renewal of the intestinal mucosa. Recent advances in the identification and culture of intestinal stem cells have improved our understanding of the interactions between the microbiome and the immune ...
James L M, Ferrara, Mohammed S, Chaudhry
openaire +5 more sources
Case Report: Successful treatment of steroid-refractory graft-vs.-host disease following bilateral lung transplantation [PDF]
Frontiers in TransplantationGraft-vs.-host disease (GVHD) is a rare but potentially fatal complication following solid organ transplantation (SOT), with limited reported cases and high mortality rates after lung transplantation. We present a case of steroid-refractory GVHD (SR-GVHD)
Benjamin J. McCormick +5 more
doaj +2 more sources
Analysis of Correlation between Body Mass Index and the Incidence of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation [PDF]
Journal of Kerman University of Medical Sciences, 2021 Background: Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Identifiying the probable risk factors can help the clinicians manage the consequences of GVHD.
Masoud Soleimani +6 more
doaj +1 more source
South Asian Journal of Cancer, 2022 Sanjeev Kumar Sharma Hematopoietic stem cell transplantation (HSCT) is the preferred treatment for high-risk and relapsed/refractory hematological malignancies.
Sanjeev Kumar Sharma +6 more
doaj +1 more source
Controversies and expectations for the prevention of GVHD: A biological and clinical perspective
Frontiers in Immunology, 2022 Severe acute and chronic graft versus host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation.
Benjamin Watkins, Kirsten M. Williams
doaj +1 more source
Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans
Frontiers in Immunology, 2021 Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for hematologic malignancies, but its success is complicated by graft-versus-host disease (GVHD). GVHD can be divided into acute and chronic types.
Qingxiao Song +8 more
doaj +1 more source
Oral Manifestations of Graft vs. Host Disease: A Comprehensive Review for Best Practice in Dentistry
Medicina, 2023 Graft-versus-host disease (GVHD) is a complication of hematopoietic stem cell transplantation (HSCT). GVHD may also develop following solid transplants or blood transfusions if white blood cells are transferred.
Michele Miranda +5 more
doaj +1 more source
Frontiers in Medicine, 2023 IntroductionAcute gastrointestinal graft-versus-host disease (GVHD) is a common life-threatening complication after hematopoietic stem cell transplantation (HCT).
Eun Sil Kim +8 more
doaj +1 more source